For days, at the sites of Sanofi Pasteur(1) in Val de Reuil in France, Swiftwater in the United States, Shenzhen in China and Ocoyoacac in Mexico, a fleet of trucks delivers a valuable and fragile cargo: several hundred thousand chicken eggs. In January the race against the clock for the manufacture of the flu vaccine in the Northern Hemisphere begins while that for the Southern Hemisphere is not yet over. In February, the WHO makes its predictions on the dominant strains after months of monitoring the circulation of viruses throughout the world. The vaccine will be manufactured according to the WHO’s recommendations and must be delivered before the start of the influenza season.

The countdown
From January to May: The millions of eggs have been delivered. Each egg receives a viral strain, then is incubated to allow the virus to multiply. Next, a liquid or serum of virus is harvested, then purified in several stages, filtered and treated to fragment and "kill" the virus. Inactivating a virus so that it is not pathogenic during the injection, in order to induce an immune reaction, is a complex process. The operation is repeated for each of the four viral strains incorporated in the so-called “quadrivalent” vaccine.

The importance of the egg
At each stage, quality control tests are carried out on the four different strains for the purity, sterility and viral concentration that will determine the effectiveness of the future vaccine. "The vaccines are intended for healthy people, requiring the highest standards of quality and safety and increasing the complexity of their production," explains Florence Brunel, Head of Global Programs Execution for Industrial Affairs, Sanofi Pasteur.


In search of a broadly-protective vaccine
One of the peculiarities of influenza viruses is their amazing ability to mutate. This not only complicates the task of the manufacturer but may reduce the effectiveness of the vaccine when the mutation occurs during the influenza season. Sanofi is actively exploring several of the major influenza vaccination strategies to develop a broadly-protective vaccine designed to address these seasonal changes. Research that is performed internally as well as externally with the University of Georgia, Boston-based biotech company BERG and SK Chemicals, based in South Korea with which we have reached an agreement on the cell culture technology.
"The ultimate goal is to develop a truly universal vaccine; but we expect, as a first step, to replace the current seasonal vaccine, requiring annual administration, with a broadly-protective vaccine," says John Shiver, Senior Vice President, Research and Development at Sanofi Pasteur. "Science, and particularly vaccine R&D, is an iterative process. It's an evolution."
Reference
(1) Sanofi Pasteur is Sanofi's Global Business Unit dedicated to vaccines